Linezolid is a relatively novel oxazolidinone and its use is currently limited to secondary care in the UK. It is a reversible, non-selective monoamine oxidase inhibitor, but at the doses used for antibacterial therapy it does not exert an anti-depressive effect. It has a potentially serious side effect profile and is monitored intensively by the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency. Herein we report the rarely recognised complication of linezolid-induced hypoglycaemia in a patient with type 1 diabetes.
BoultonAJVileikyteLRagnarson-TennvallGApelqvistJ. The global burden of diabetic foot disease. Lancet2005;366:1719-24.
2.
PrompersLHuijbertsMSchaperN. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia2008;51:1826-34.
3.
VuorisaloSVenermoMLepantaloM. Treatment of diabetic foot ulcers. J Cardiovasc Surg (Torino)2009;50:275-91.
4.
LipskyBABerendtARDeeryHG. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis2004;39:885-910.
5.
VinhDCRubinsteinE. Linezolid: a review of safety and tolerability. J Infect2009;59(suppl 1):S59-74.
BodnarTStarrKHalterJB. Linezolid-associated hypoglycemia in a 64-year-old man with type 2 diabetes. Am J Geriatr Pharmacother2011;9:88-92.
10.
AdnittPI. Monoamineoxidase inhibition and insulin sensitivity. J Endocrinol1968;42:417-23.
11.
CooperAJAshcroftG. Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs. Lancet1966;1:407-9.
12.
McIntyreRSSoczynskaJKKonarskiJZKennedySH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf2006;5:157-68.
13.
DrozakJKozlowskiMDoroszewskaR. Differential effects of selegiline on glucose synthesis in rabbit kidney-cortex tubules and hepatocytes. In vitro and in vivo studies. Chem Biol Interact2007;170:162-76.
14.
GazianoJMCincottaAHO’ConnorCM. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care2010;33:1503-8.
